Anthony Ling

Optimization of Alkylidene Hydrazide Based Human Glucagon Receptor Antagonists. Discovery of the Highly Potent and Orally Available 3-Cyano-4-hydroxybenzoic Acid [1-(2,3,5,6-Tetramethylbenzyl)-1<i>H</i>-indol-4-ylmethylene]hydrazide

Peter Madsen, Anthony Ling, Michael Plewe et al. · Journal of Medicinal Chemistry · 2002 · 87 citations · Full text

Students as customers: The expectations and perceptions of local and international students

Carol Sherry, Ravi Bhat, Bob Beaver et al. · 2004 · 72 citations · Full text

Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus

Jeffrey A. Pfefferkorn, Angel Guzmán-Pérez, Peter J. Oates et al. · MedChemComm · 2011 · 68 citations

New β-Alanine Derivatives Are Orally Available Glucagon Receptor Antagonists

Jesper Lau, Carsten Behrens, Ulla G. Sidelmann et al. · Journal of Medicinal Chemistry · 2007 · 53 citations · Full text

Molecular Pharmacology, Potent Glucagon Antagonist, Biochemistry +13

Identification of Alkylidene Hydrazides as Glucagon Receptor Antagonists

Anthony Ling, Yufeng Hong, Javier González et al. · Journal of Medicinal Chemistry · 2001 · 42 citations · Full text

Medicinal Chemistry, Drug Target, Biochemistry +15